Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries

Data de publicação:

Autores da FMUP

  • Nuno Miguel De Sousa Lunet

    Autor

Participantes de fora da FMUP

  • Yoo, SGK
  • Chung, GS
  • Bahendeka, SK
  • Sibai, AM
  • Damasceno, A
  • Farzadfar, F
  • Rohloff, P
  • Houehanou, C
  • Norov, B
  • Karki, KB
  • Azangou-Khyavy, M
  • Marcus, ME
  • Aryal, KK
  • Brant, LCC
  • Theilmann, M
  • Cífková, R
  • Gurung, MS
  • Mwangi, JK
  • Martins, J
  • Haghshenas, R
  • Sturua, L
  • Vollmer, S
  • Bärnighausen, T
  • Atun, R
  • Sussman, JB
  • Singh, K
  • Saeedi Moghaddam, S
  • Guwatudde, D
  • Geldsetzer, P
  • Manne-Goehler, J
  • Huffman, MD
  • Davies, JI
  • Flood, D

Unidades de investigação

Abstract

IMPORTANCE Aspirin is an effective and low-cost option for reducing atherosclerotic cardiovascular disease (CVD) events and improving mortality rates among individuals with established CVD. To guide efforts to mitigate the global CVD burden, there is a need to understand current levels of aspirin use for secondary prevention of CVD. OBJECTIVE To report and evaluate aspirin use for secondary prevention of CVD across low-, middle-, and high-income countries. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional analysis using pooled, individual participant data from nationally representative health surveys conducted between 2013 and 2020 in 51 low-, middle-, and high-income countries. Included surveys contained data on self-reported history of CVD and aspirin use. The sample of participants included nonpregnant adults aged 40 to 69 years. EXPOSURES Countries' per capita income levels and world region; individuals' socioeconomic demographics. MAIN OUTCOMES AND MEASURES Self-reported use of aspirin for secondary prevention of CVD. RESULTS The overall pooled sample included 124505 individuals. The median age was 52 (IQR, 45-59) years, and 50.5% (95% CI, 49.9%-51.1%) were women. A total of 10589 individuals had a self-reported history of CVD (8.1% [95% CI, 7.6%-8.6%]). Among individuals with a history of CVD, aspirin use for secondary prevention in the overall pooled sample was 40.3% (95% CI, 37.6%-43.0%). By income group, estimates were 16.6% (95% CI, 12.4%-21.9%) in low-income countries, 24.5% (95% CI, 20.8%-28.6%) in lower-middle-income countries, 51.1% (95% CI, 48.2%-54.0%) in upper-middle-income countries, and 65.0% (95% CI, 59.1%-70.4%) in high-income countries. CONCLUSION AND RELEVANCE Worldwide, aspirin is underused in secondary prevention, particularly in low-income countries. National health policies and health systems must develop, implement, and evaluate strategies to promote aspirin therapy.

Dados da publicação

ISSN/ISSNe:
1538-3598, 0098-7484

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION  American Medical Association

Tipo:
Article
Páginas:
715-724
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 1

Citações Recebidas na Scopus: 10

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • MEDICATION USE; COLLABORATIVE METAANALYSIS; THERAPY

Financiamento

Proyectos asociados

Breast cancer heterogeneity - etiology, clinical management, use of health resources and survival

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2022

Longitudinal Assessment of Cognitive Decline in Breast and Prostate Cancer Survivors

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico (Cognitive Decline) . 2022

Healthcare use among cancer patients and their partners in different phases of the cancer pathway

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2021

Reshaping organized cervical cancer screening: strategies to increase the adherence and reduce invitation costs

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2020

Using pooled analyses based on individual participant data for a finer assessment of gastric cancer etiology

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2020

RISK AND SURVIVAL OF GASTRIC CANCER RELATES SECOND PRIMARY TUMOURS: A COMPETING RISKS FRAMEWORK

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2019

Citar a publicação

Partilhar a publicação